Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds. It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014, becoming the first approved therapy against PD-1. In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers.
Pembrolizumab is indicated for the following conditions:
For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.
Seattle Cancer Care Alliance, Seattle, Washington, United States
Seoul National University Hospital, Seoul, Korea, Republic of
Samsung Medical Center, Seoul, Korea, Republic of
University of California San Francisco, San Francisco, California, United States
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Eisai Trial Site 1, Chuo-ku, Tokyo, Japan
Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway
University of Maryland Comprehensive Cancer Center, Baltimore, Maryland, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Houston Methodist Cancer Center, Houston, Texas, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
USC Keck School of Medicine, Norris Cancer Center, Los Angeles, California, United States
Weill Cornell Medicine, New York, New York, United States
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
UCLH, London, United Kingdom
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.